Form 4: CRISPR Therapeutics AG: Officer Julianne Bruno Awarded Stock Options

Julianne Bruno, Chief Operating Officer of CRISPR Therapeutics AG, was granted stock options for 18,333 common shares on October 16, 2024.

Summary

• Julianne Bruno, the Chief Operating Officer of CRISPR Therapeutics AG, received stock options on October 16, 2024.
• The options grant covers 18,333 common shares.
• The exercise price of the options is $49.
• The options vest in 48 equal monthly installments, starting November 16, 2024.
• The options expire on October 16, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports a standard stock option grant to an executive. It's a common practice and doesn't inherently indicate positive or negative news.

Positives

• The grant of stock options to the COO aligns her interests with those of the shareholders.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies like Editas Medicine and Intellia Therapeutics also utilize stock options as part of their executive compensation strategy.
• The vesting schedule of 48 months is a typical vesting period for stock options.

Key Dates